comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 02:28:13 - browse：4

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Eli Lilly expects to double planned employment in Boston center

WSS

Beam Therapeutics to lay off 20% of its staff, re

How climate

HHS leader on health, climate change and biopharma emissions

Doctors on social media are being harassed and cyberbullied

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Hospital price transparency does save money, advocate argues

leisure time

comprehensive

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Study gives hint on South Asians’ higher risk of cardiovascular disease

Medical records are filled with copy

The explosion of genetic testing requires a new approach

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Wildfire smoke exposes gaps in outdoor worker protections

Why don't Americans have at

ChatGPT in medicine: STAT answers readers' burning questions

Tome Biosciences co

Wikipedia

FDA struggles to regulate food additives, sometimes for decades

STAT Summit: Biotech founders on deal

FDA struggles to regulate food additives, sometimes for decades

Hospital price transparency does save money, advocate argues

NIH confirmation hearing shows politicization of research

Beam Therapeutics to lay off 20% of its staff, re

entertainment

entertainment

explore

focus